哈尔滨誉衡药业股份有限公司 哈尔滨誉衡药业股份有限公司 敏感信息排查管理制度 公司各部门及子公司应建立报告义务人名单并根据人员岗位变动情况及时对 该名单进行调整。各部门及子公司报告义务人名单应及时报送公司董事会办公 室。除上述人员外，以下人员同为报告义务人： 第 1页 第一条 哈尔滨誉衡药业股份有限公司（以下简称"公司"）为进一步规范信息披露工 作、提高公司治理水平、加强公司敏感信息的相关管理、保护公司和投资者合 法权益，根据《深圳证券交易所股票上市规则》、《深圳证券交易所上市公司自 律监管指引第 1 号——主板上市公司规范运作》等有关法律法规、规范性文件 及《公司章程》等有关规定，结合公司实际情况，特制定本制度。 第二条 本制度所称敏感信息是指在公司生产经营活动中出现、发生或即将发生会明显 影响社会公众投资者投资取向，或会对公司股票及其衍生品种的交易价格产生 较大影响的情形以及网络、报刊、电视、电台等媒体对本公司的报道、传闻等。 公司对涉及公司的重大报道或传闻，如经营业绩、并购重组、签订或解除重大 合同等事项将进行内部信息自查，向股东、实际控制人等相关方进行核实。 第三条 公司各部门（包括公司内部各职能部门 ...

哈尔滨誉衡药业股份有限公司 哈尔滨誉衡药业股份有限公司 第三条 募集资金到位后，公司应及时办理验资手续，由具有证券从业资格 的注册会计师事务所出具验资报告。 第四条 公司董事会负责建立健全募集资金管理制度，对募集资金专户存储、 管理、使用、变更、监督以及分级审批权限、决策程序、风险控制措施、信息披 露程序和和责任追究等内容进行明确规定，并确保该制度的有效实施。 公司董事会应当持续关注募集资金存放、管理和使用情况，有效防范投资风 险，提高募集资金使用效益。 第五条 公司募集资金投资项目通过公司的子公司或公司控制的其他企业实 施的，公司应当确保该子公司或控制的其他企业遵守本制度。 第二章 募集资金专户存储 募集资金使用管理制度 第一章 总则 第一条 为规范哈尔滨誉衡药业股份有限公司（以下简称"公司"）募集资金 管理，提高募集资金使用效率，根据《公司法》、《证券法》、《上市公司募集资金 监管规则》、《深圳证券交易所股票上市规则》（以下简称"《股票上市规则》"）、 《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》等 有关法律、法规、规章、规范性文件和《公司章程》有关规定，特制定本制度。 第二条 ...

誉衡药业公告，2025年上半年，公司实现营业收入11亿元，同比下降9.97%；归属于上市公司股东的净 利润1.34亿元，同比增长7.56%；基本每股收益0.0613元/股，同比增长10.25%。 ...

哈尔滨誉衡药业股份有限公司 2025 年半年度报告 2025 年 8 月 第 1页 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实、准确、完整，不存在虚假记载、误 导性陈述或者重大遗漏，并承担个别和连带的法律责任。 证券代码：002437 证券简称：誉衡药业 公告编号：2025-062 公司负责人国磊峰、主管会计工作负责人国磊峰及会计机构负责人(会计主管人员)周小婧声明：保证本半年度报告 中财务报告的真实、准确、完整。 所有董事均已出席了审议本次半年报的董事会会议。 本公司风险因素详见"第三节 管理层讨论与分析-十、公司面临的风险和应对措施" 公司计划不派发现金红利，不送红股，不以公积金转增股本。 第 2页 | 第一节 | 重要提示、目录和释义 | | 2 | | --- | --- | --- | --- | | 第二节 | 公司简介和主要财务指标 | | 6 | | 第三节 | 管理层讨论与分析 | | 9 | | 第四节 | 公司治理、环境和社会 | | 20 | | 第五节 | 重要事项 | | 23 | | 第六节 | 股份变动及股东情况 | | ...

Group 1 - The core point of the article is that Yuheng Pharmaceutical has seen a decrease in the number of shareholders and fluctuations in its stock price, alongside mixed financial performance in the first quarter [2] Group 2 - As of August 10, the number of shareholders for Yuheng Pharmaceutical was 121,400, a decrease of 10,500 from the previous period, representing a decline of 7.96% [2] - The closing price of Yuheng Pharmaceutical on the reporting date was 3.73 yuan, down 0.80%, with a cumulative increase of 0.54% since the concentration of shares began [2] - The stock experienced 4 days of price increases and 7 days of declines during the reporting period [2] Group 3 - The latest margin trading data as of August 15 shows a total margin balance of 563 million yuan, with a financing balance of 563 million yuan, indicating an increase of 131 million yuan, or 30.31%, since the concentration of shares began [2] Group 4 - In the first quarter, Yuheng Pharmaceutical reported total revenue of 551 million yuan, a year-on-year decrease of 7.06%, while net profit was 60.25 million yuan, a year-on-year increase of 15.24% [2] - The basic earnings per share were 0.0274 yuan, and the weighted average return on net assets was 3.08% [2]

Group 1 - The stock price of Yuheng Pharmaceutical is reported at 3.75 yuan as of August 5, 2025, reflecting a decrease of 0.06 yuan or 1.57% from the previous trading day [1] - The company operates in the chemical pharmaceutical sector, focusing on drug research, production, and sales [1] - Yuheng Pharmaceutical has not met the conditions for dividend distribution due to accumulated unremedied losses being negative [1] Group 2 - The company completed a share repurchase plan in March 2025, buying back a total of 32.3072 million shares at a cost of approximately 80 million yuan [1] - On August 5, the stock experienced a rapid rebound with an increase of over 2% within five minutes, but subsequently fell back [1] - The net outflow of main funds on that day was 7.9332 million yuan, while there was a net inflow of 100 million yuan over the past five days [1]

证券日报网讯 誉衡药业8月5日在互动平台回答投资者提问时表示，公司目前累计未弥补亏损为负，暂 不满足分红条件。但公司推出的股份回购方案已于2025年3月实施完毕，累计使用资金约8，000万元， 回购股份数量3，230.72万股。根据相关法律、法规的规定，公司以集中竞价方式回购公司股份视同现 金分红，公司通过本次回购计划，积极回馈长期以来支持与信任公司的广大投资者。 （编辑 王雪儿） ...

Group 1 - The chemical pharmaceutical sector increased by 0.48% on August 4, with Hai Chen Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 3583.31, up 0.66%, while the Shenzhen Component Index closed at 11041.56, up 0.46% [1] - Hai Chen Pharmaceutical's stock price rose by 20.01% to 41.27, with a trading volume of 285,300 shares and a transaction value of 1.101 billion [1] Group 2 - The top gainers in the chemical pharmaceutical sector included Han Yu Pharmaceutical, which rose by 19.98% to 24.32, and Guangsheng Tang, which increased by 18.18% to 120.90 [1] - The sector saw a net inflow of 97.0043 million in main funds, while retail investors contributed a net inflow of 1.279 billion [2] - The main funds showed significant net outflows in several companies, including Hai Chen Pharmaceutical, which had a net inflow of 182 million, but retail investors had a net outflow of 579.696 million [3]

Core Insights - Harbin Yuheng Pharmaceutical Co., Ltd. (誉衡药业) reported a stock price of 4.04 yuan as of August 1, 2025, reflecting an increase of 8.89% with a turnover rate of 22.96% and a trading volume of 4.8238 million hands, amounting to 1.913 billion yuan in transaction value [1] Financial Performance - For Q1 2025, the company recorded total revenue of 551 million yuan, a year-on-year decrease of 7.06%, while net profit attributable to shareholders was 60.2523 million yuan, showing a year-on-year increase of 15.24%. The non-recurring net profit was 49.733 million yuan, up 54.74% year-on-year [1] - The company's liquidity ratios include a current ratio of 1.061, a quick ratio of 0.853, and a debt-to-asset ratio of 31.97% [1] Investment and Intellectual Property - Harbin Yuheng Pharmaceutical has made investments in 19 companies and participated in 423 bidding projects. The company holds 701 trademark registrations and 28 patents, along with 9 administrative licenses [2]

Group 1 - The core viewpoint of the news highlights the recent stock performance of Yuheng Pharmaceutical, which saw an increase of 8.01% on July 31, reaching a price of 3.91 yuan per share with a trading volume of 8.85 billion yuan and a turnover rate of 11.38%, resulting in a total market capitalization of 87.81 billion yuan [1] - Yuheng Pharmaceutical, based in Harbin, Heilongjiang Province, is a modern pharmaceutical company that integrates research, production, and sales, initially focusing on orthopedic treatments and expanding into cardiovascular and other therapeutic areas, establishing a product cluster that includes cardiovascular, musculoskeletal, and nutritional medications [1] - The company emphasizes strict quality management and international innovation, having established production bases and marketing systems that comply with GMP and GSP standards, while actively developing CMO platforms and chronic disease services, aiming to become a leading pharmaceutical enterprise in China with an international perspective [1] Group 2 - As of May 30, Yuheng Pharmaceutical had 107,100 shareholders, with an average of 19,600 circulating shares per shareholder [2] - For the first quarter of 2025, Yuheng Pharmaceutical reported a revenue of 551 million yuan, a year-on-year decrease of 7.06%, while the net profit attributable to shareholders was 60.25 million yuan, reflecting a year-on-year increase of 15.24% [2]